Prostacyclin in the Treatment of Atherosclerosis Obliterans and Other Vascular Diseases

  • R. J. Gryglewski
  • A. Szczeklik
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


Prostacyclin is the main arachidonic acid metabolite produced by the arterial walls (2,3,7) and released into circulation (1,4). In man, prostacyclin acts as a powerful vasodilator and anti-platelet agent (13). Resistance vessels are most susceptible for prostacyclin vasodilatory action, while capacitance vessels show little, if any change, even during administration of high doses of prostacyclin (18). The profound anti-platelet effects induced by prostacyclin can be devided into anti-aggregatory and disaggregatory (5,12,13). The former are reflected by a marked inhibition of ADP — or collagen — induced platelet aggregation, the latter by dispersion of both circulating platelet aggregates and platelet thrombi formed on the collagen surface.


Pulmonary Hypertension Retinal Vein Occlusion Central Retinal Vein Occlusion Pulmonary Artery Hypertension Induce Platelet Aggregation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.J. Gryglewski, Prostacyclin as a circulating hormone. Biochem. Pharmacol. 28: 3161 (1979).PubMedCrossRefGoogle Scholar
  2. 2.
    R.J. Gryglewski, Prostaglandins, platelets, and atherosclerosis. CRC series in Biochemistry 7: 291 (1980).CrossRefGoogle Scholar
  3. 3.
    R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower, J.R. Vane, Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12: 685 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    R.J. Gryglewski, R. Korbut, A. Ocetkiewicz, Generation of prostacyclin by lungs in vivo and its release into arterial circulation. Nature 273: 765 (1978).PubMedCrossRefGoogle Scholar
  5. 5.
    R.J. Gryglewski, A. Szczeklik, R. Nizankowski, Antiplatelet action of intravenous prostacyclin in man. Thrombos. Res. 13:152 (1978).CrossRefGoogle Scholar
  6. 6.
    R.J. Gryglewski, A. Szczeklik, H. Zygulska-Mach, E. Kostaka-Trabka, Prostacyclin and vascular disease. Symposium A. Einstein Coll. of Med., 28–30 October 1980. Raven Press, New York — in press.Google Scholar
  7. 7.
    S. Moncada, R.J. Gryglewski, S. Bunting, J.R. Vane, A lipid peroxide inhibits the enzyme that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelets from aggregation. Prostaglandins 12: 715 (1976).PubMedCrossRefGoogle Scholar
  8. 8.
    A. Szczeklik, Prostacyclin and atherosclerosis. Triangle 19: 61 (1980).PubMedGoogle Scholar
  9. 9.
    A. Szczeklik, Cardiovascular actions of prostacyclin in man. International conference on prostaglandins, New york, April 1980, in press.Google Scholar
  10. 10.
    A. Szczeklik, R.J. Gryglewski, Treatment of vascular disease with prostacyclin. In Clinical pharmacology of prostacyclin, ed. by P. Lewis and J. O’Grady, in press.Google Scholar
  11. 11.
    A. Szczeklik, R.J. Gryglewski, Prostaglandins as therapeutical agents in cardiovascular disease. Proceedings of the meeting “Prostaglandins and the cardiovascular system”, Wilrijk (Belgium) 1–3 December 1980, in press (Raven Press).Google Scholar
  12. 12.
    A. Szczeklik, R.J. Gryglewski, E. Nizankowska, R. Nizankowski, J. Musial, Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 16: 651 (1978).CrossRefGoogle Scholar
  13. 13.
    A. Szczeklik, R.J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, J. Murk, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol. Res. Commun. 10: 545 (1978).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Szczeklik, R.J. Gryglewski, R. Nizankowski, S. Skawinski, P. Gluszko, Prostacyclin therapy of peripheral vascular disease. Thrombos. Res. 19: 191 (1980).CrossRefGoogle Scholar
  15. 15.
    A. Szczeklik, R. Nizankowski, S. Skawinski, J. Szczeklik, P. Gluszko, R.J. Gryglewski, Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1: 1111 (1979).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszco, Prostacyclin for unstable angina. N. Engl. J. Med. 303: 881 (1980).PubMedGoogle Scholar
  17. 17.
    A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszko, Prostacyclin for acute coronary insufficiency. Artery — in press.Google Scholar
  18. 18.
    J. Szczeklik, A. Szczeklik, R. Nizankowski, Haemodynamic changes induced by prostacyclin in man. Br. Heart J. 44: 254 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    J. Szczeklik, A. Szczeklik, R. Nizankowski, Prostacyclin for pulmonary hypertension. Lancet 2: 1076 (1980).PubMedCrossRefGoogle Scholar
  20. 20.
    W.D. Watkins, M.P. Peterson, R.K. Brone, D.C. Shannon, L. Levine, Prostacyclin and prostaglandin E. for severe pulmonary artery hypertension. Lancet 1: 1083 (1980).PubMedCrossRefGoogle Scholar
  21. 21.
    H. Zygulska-Mach, E. Kostka-Trabka, A. Niton, R.J. Gryglewski, Prostacyclin in central retinal vein occlusion. Lancet 2: 1075 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • R. J. Gryglewski
    • 1
  • A. Szczeklik
    • 1
  1. 1.Departments of Pharmacology and Internal MedicineCopernicus Academy of MedicineCracowPoland

Personalised recommendations